Drug Profile

Cefepime oral - Seachaid Pharmaceuticals

Alternative Names: SP-1001

Latest Information Update: 26 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Seachaid Pharmaceuticals
Class Anti-infectives; Antibacterials; Cephalosporins; Small molecules; Urinary anti-infective agents
Mechanism of Action Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

26 Sep 2025 No development reported - Phase-I for Urinary tract infections (PO) (Seachaid Pharmaceuticals website, September 2025)
31 Aug 2023 Cefepime oral (SP 1001) is still in preclinical phase for urinary tract infections in USA (Seachaid Pharmaceuticals pipeline, August 2023)
31 Aug 2023 Phase-I clinical trials in Urinary tract infections (PO) (Seachaid Pharmaceuticals pipeline, August 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com